[1] 单姗,赵连晖,马红等.肝硬化的定义、病因及流行病学[J].临床肝胆病杂志,2021, 37(1):14-16.DOI:10.3969/j.issn.1001-5256.2021.01.003.
[2] 赫捷,陈万青,沈洪兵,等.中国人群肝癌筛查指南(2022,北京)[J].临床肝胆病杂志, 2022, 38(8):1739-1758.DOI:10.3969/j.issn.1001-5256.2022.08.007.
[3] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al.Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people[J]. Age Ageing,2010,39(4):412-423.DOI:10.1093/ageing/afq034.
[4] 中华医学会肝病学分会,中华医学会消化病学分会.终末期肝病临床营养指南[J].中华肝脏病杂志,2019,27(5):330-342.DOI:10.3760/cma.j.issn.1007-3418.2019.05.003.
[5] Periyalwar P, Dasarathy S.Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses[J].Clin Liver Dis,2012,16(1):95-131.DOI: 10.1016/j.cld.2011.12.009.
[6] Kim HY, Jang JW.Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score[J].World J Gastroenterol,2015,21(25):7637-7647. DOI:10.3748/wjg.v21.i25.7637.
[7] Hanai T, Shiraki M, Nishimura K, et al.Sarcopenia impairs prognosis of patients with liver cimrhosis[J]. Nutition,2015,31(1):193-199.DOI:10.1016.j.nut.2014.07.005.
[8] 肖慧娟,叶青,张明,等.肝硬化合并肌肉减少症的危险因素及其对临床结局的影响[J].中华肝脏病杂志, 2020,28(1):53-57.DOI:10.3760/cma.j.issn.1007-3418.2020.01.013.
[9] 王贵强,王福生,庄辉,等.慢性乙型肝炎防治指南(2019年版)[J].中国病毒病杂志,2020,10(1):1-25.DOI:10.16505/j.2095-0136.2019.0097.
[10] 徐勇勇,孙振球.医学统计学[M].4版.北京:人民出版社,2014:35-36.
[11] Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status?[J]. JPEN J Parenter Enteral Nutr, 1987,11(1):8-13.DOI:10.1177/014860718701100108.
[12] 屈宁宁,李可基.国际体力活动问卷中文版的信度和效度研究[J].中华流行病学杂志,2004(3):87-90.DOI:10.3760/j.issn:0254-6450.2004.03.021.
[13] 卢婷,应燕萍,赵慧涵,等.恶性肿瘤患者握力的影响因素分析[J].护理学报,2020,27(6):1-4.DOI:10.16460/j.issn1008-9969.2020.06.001.
[14] 杨卉,崔云婧,张少景,等. 步速和握力对住院老年患者全因死亡和跌倒的预测价值研究[J]. 中国全科医学,2022,25(32):4010-4017. DOI:10.12114/j.issn.1007-9572.2022.0355.
[15] 张亮,郑鹏.L3水平CT横截面机体组成改变对结直肠癌病人生存预后的价值分析[J].肠外与肠内营养,2023,30(4):226-233.DOI:10.16151/j.1007-810x.2023.04.006.
[16] Tandon P, Ney M, Irwin I, et al.Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value[J]. Liver Transpl, 2012,18(10):1209-1216. DOI:10.1002/lt.23495.
[17] Cruz RJ Jr., Dew MA, Myaskovsky L, et al.Objective radiologic assessment of body composition in patients with end-stage liver disease: going beyond the BMI[J]. Transplantation,2013, 95(4):617-622.DOI:10.1097/TP.0b013e31827a0f27.
[18] DiMartini A, Cruz RJ Jr, Dew MA, et al. Muscle mass predicts outcomes following liver transplantation[J]. Liver Transpl,2013,19(11): 1172-1180. DOI:10.1002/lt.23724.
[19] Hara N, Iwasa M, Sugimoto R, et al.Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis[J]. Intern Med,2016,55(8):863-870. DOI:10.2169/internalmedicine.55.5676.
[20] Yadav A, Chang YH, Carpenter S, et al.Relationship between sarcopenia,six-minute walk distance and health-related quality of life in liver transplant candidates[J]. Clin Transplant, 2015,29(2):134-141. DOI:10.1111/ctr.12493.
[21] 杨诚,杨华升,胡建华,等.终末期肝病与营养相关研究的可视化分析[J].肝脏,2023,28(1):65-69. DOI:10.3969/j.issn.1008-1704.2023.01.017.
[22] 赵林. 线粒体功能障碍控制急慢性肝衰竭患者白细胞的免疫代谢[J].广东药科大学学报,2022,38(1):22.
[23] 柯飒,邓媛媛,章鑫煦,等.慢性乙型肝炎患者糖代谢异常的研究进展[J].中国感染控制杂志,2019, 18(7):696-700. DOI:10.12138/j.issn.1671-9638.20195233.
[24] 周志文,李姗,刘湘花,等.中药单体调控氧化应激抗肝纤维化的机制和价值[J].临床肝胆病杂志,2021,37(9):2198-2202. DOI:10.3969/j.issn.1001-5256.2021.09.039.
[25] Leenders M, Verdijk LB, van der Hoeven L, et al. Prolonged leucine supplementation does not augment muscle mass or affect glycemic control in elderly type 2 diabetic men[J]. J Nutr,2011,141(6):1070-1076. DOI:10.3945/jn.111.138495.
[26] 中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志,2018,34(10):2076-2089. DOI:10.3969/j.issn.1001-5256.2018.10.007.
[27] 房良,荆雪,田字彬.肌肉减少症与肝硬化的临床研究进展[J].肠外与肠内营养,2018,25(5):308-312. DOI:10.16151/j.1007-810x.2018.05.013.
[28] 张一骏,张茜,罗新华.肝硬化患者营养不良和衰弱的评估与临床管理[J].临床肝胆病杂志,2022,38(7):1646-1649. DOI:10.3969/j.issn.1001-5256.2022.07.035.
[29] European Association for the Study of the Liver.EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.DOI:10.1016/j.jhep.2018.03.019.
[30] 殷悦,祁兴顺,杨永平. 肝硬化患者营养状态的评估及管理[J]. 解放军医学杂志,2023,48(1):13-17.DOI:10.11855/j.issn.0577-7402.2023.01.0013.
[31] Periyalwar P, Dasarathy S.Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses[J]. Clin Liver Dis, 2012,16(1):95-131.DOI:10.1016/j.cld.2011.12.009.
[32] 郭俏凤,甘彦明,张宇航等.抗阻运动对糖、脂代谢异常人群效果的 Meta 分析[J].中国循证医学杂志,2021,21(12):1432-1440.DOI:10.7507/1672-2531.202107086.
[33] Sirisunhirun P, Bandidniyamanon W, Jrerattakon Y, et al.Effect of a 12-week home-based exercise training program on aerobic capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a randomized controlled clinical trial[J]. BMC Gastroenterol,2022,22(1):66.DOI:10.1186/s12876-022-02147-7.